Skip to content

LIGAND PHARMACEUTICALS INC

LGND

Latest QuantConomy context for LGND: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
20
Asset profile

LIGAND PHARMACEUTICALS INC

QuantConomy has a structured record for LGND. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
LGND
Name
LIGAND PHARMACEUTICALS INC
Coverage
3 market/data records
Sources
fmp alpaca alphavantage sec nasdaq openfigi
Latest signal rows

Recent signals for LGND

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
standard proposed sale
slightly bearish
36
Jul 1, 09:00 PM ANDREW REARDON filed Form 144 to sell LGND shares ($3.16M) - 10,000 shares - expected around 7/1/2026 - [weak slightly bearish signal - supply pressure]
material agreement
bullish
90
Jun 25, 09:05 PM LGND filed 8-K: Material Definitive Agreement, Direct Financial Obligation, Unregistered Sales of Equity - 4 material events - [very strong bullish signal]
earnings release
neutral
40
Feb 26, 12:00 AM LGND filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-26. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

PROPOSED_SALE signals are experimental: historical Form 144 coverage is still being backfilled, so results may be sparse or empty.

Market coverage

Market Exchange Source Asset record
LGND NASDAQ fmp Ligand Pharmaceuticals Incorporated
LGND NASDAQ alpaca Ligand Pharmaceuticals Incorporated Common Stock
LGND NASDAQ alphavantage Ligand Pharmaceuticals Inc - Class B

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
1
Rows
20
Date Insider Role Type Shares Price Value Filing
Jun 30, 2026 Davis Todd C Chief Executive Officer other 132 $160.71 $21,214 4 on EDGAR
Jun 30, 2026 Espinoza Octavio Chief Financial Officer other 17 $160.71 $2,732 4 on EDGAR
Jun 30, 2026 Reardon Andrew CLO & Secretary other 132 $160.71 $21,214 4 on EDGAR
Jun 16, 2026 Sabba Stephen L Insider exercise 2,145 $66.13 $141,849 4 on EDGAR
Jun 12, 2026 Haas Jason Insider exercise 3,000 $51.56 $154,680 4 on EDGAR
Jun 5, 2026 LAMATTINA JOHN L Insider grant 836 $0.00 $0 4 on EDGAR
Jun 5, 2026 Haas Jason Insider grant 836 $0.00 $0 4 on EDGAR
Jun 5, 2026 Zimmermann Martine Insider grant 836 $0.00 $0 4 on EDGAR
Jun 5, 2026 Sabba Stephen L Insider grant 836 $0.00 $0 4 on EDGAR
Jun 5, 2026 KOZARICH JOHN W Insider grant 836 $0.00 $0 4 on EDGAR
Jun 5, 2026 Gray Nancy Ryan Insider grant 836 $0.00 $0 4 on EDGAR
Jun 5, 2026 Aryeh Jason Insider grant 836 $0.00 $0 4 on EDGAR
Jun 1, 2026 Reardon Andrew CLO & Secretary exercise 5,000 $52.27 $261,350 4 on EDGAR
May 27, 2026 Espinoza Octavio Chief Financial Officer exercise 764 $63.62 $48,606 4 on EDGAR
May 1, 2026 KOZARICH JOHN W Insider sale 80 $227.37 $18,189 4 on EDGAR
May 1, 2026 Reardon Andrew CLO & Secretary exercise 5,000 $52.27 $261,350 4 on EDGAR
Apr 1, 2026 Reardon Andrew CLO & Secretary exercise 5,000 $52.27 $261,350 4 on EDGAR
Apr 1, 2026 KOZARICH JOHN W Insider sale 146 $199.97 $29,196 4 on EDGAR
Mar 23, 2026 Sabba Stephen L Insider sale 1,000 $207.87 $207,873 4 on EDGAR
Mar 11, 2026 Espinoza Octavio Chief Financial Officer exercise 2,405 $92.65 $222,823 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query LGND context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access